These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22986534)

  • 21. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.
    Sehrawat A; Kim SH; Vogt A; Singh SV
    Carcinogenesis; 2013 Apr; 34(4):864-73. PubMed ID: 23276794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
    Xie C; Jiang XH; Zhang JT; Sun TT; Dong JD; Sanders AJ; Diao RY; Wang Y; Fok KL; Tsang LL; Yu MK; Zhang XH; Chung YW; Ye L; Zhao MY; Guo JH; Xiao ZJ; Lan HY; Ng CF; Lau KM; Cai ZM; Jiang WG; Chan HC
    Oncogene; 2013 May; 32(18):2282-91, 2291.e1-7. PubMed ID: 22797075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of osteopontin attenuates breast tumour progression in vivo.
    Chakraborty G; Jain S; Patil TV; Kundu GC
    J Cell Mol Med; 2008 Dec; 12(6A):2305-18. PubMed ID: 18266970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
    Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
    Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA binding protein POP7 regulates ILF3 mRNA stability and expression to promote breast cancer progression.
    Huang Y; Zheng Y; Yao L; Qiao F; Hou Y; Hu X; Li D; Shao Z
    Cancer Sci; 2022 Nov; 113(11):3801-3813. PubMed ID: 35579257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
    Tang L; Han X
    Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.
    Pakneshan P; Têtu B; Rabbani SA
    Clin Cancer Res; 2004 May; 10(9):3035-41. PubMed ID: 15131040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules.
    Al-Alwan M; Olabi S; Ghebeh H; Barhoush E; Tulbah A; Al-Tweigeri T; Ajarim D; Adra C
    PLoS One; 2011; 6(11):e27339. PubMed ID: 22076152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
    Chang XZ; Li DQ; Hou YF; Wu J; Lu JS; Di GH; Jin W; Ou ZL; Shen ZZ; Shao ZM
    Breast Cancer Res; 2007; 9(6):R76. PubMed ID: 17980029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells.
    Pulukuri SM; Gorantla B; Dasari VR; Gondi CS; Rao JS
    Mol Cancer Res; 2010 Aug; 8(8):1074-83. PubMed ID: 20663859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator.
    Huang HY; Jiang ZF; Li QX; Liu JY; Wang T; Zhang R; Zhao J; Xu YM; Bao W; Zhang Y; Jia LT; Yang AG
    Cancer Invest; 2010 Aug; 28(7):689-97. PubMed ID: 20636107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
    Salvi A; Sabelli C; Moncini S; Venturin M; Arici B; Riva P; Portolani N; Giulini SM; De Petro G; Barlati S
    FEBS J; 2009 Jun; 276(11):2966-82. PubMed ID: 19490101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
    Kargiotis O; Chetty C; Gogineni V; Gondi CS; Pulukuri SM; Kyritsis AP; Gujrati M; Klopfenstein JD; Dinh DH; Rao JS
    Int J Oncol; 2008 Nov; 33(5):937-47. PubMed ID: 18949356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-1β-stimulated urokinase plasminogen activator expression through NF-κB in gastric cancer after HGF treatment.
    Lee KH; Choi EY; Koh SA; Kim MK; Jang BI; Kim SW; Kim JR
    Oncol Rep; 2014 May; 31(5):2123-30. PubMed ID: 24626561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
    Jo M; Takimoto S; Montel V; Gonias SL
    Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.